Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Shaheenah Dawood, Joanne Wing-yan Chiu, Chiun-Sheng Huang, Shona Nag, Aumkhae Sookprasert, Yoon-Sim Yap & Mastura Md Yusof. (2020) Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors. Current Medical Research and Opinion 36:8, pages 1363-1373.
Read now
Read now
Benjamin Walbaum, Francisco Acevedo, Lidia Medina, M. Loreto Bravo, Tomas Merino, Mauricio Camus, Francisco Dominguez, Sebastian Mondaca, Hector Galindo, Bruno Nervi, Carolina Ibañez, Jorge Madrid, Jose Peña, Erica Koch, Marcelo Garrido, Mauricio P. Pinto & César Sánchez. (2020) First-line endocrine therapy for advanced breast cancer. A real-world study at a Latin American university health institution. Current Medical Research and Opinion 36:7, pages 1195-1199.
Read now
Read now
Tanya Burton, Stacey DaCosta Byfield, Gregory L. Smith, Giovanni Zanotti, Timothy J. Bell, Julia J. Perkins, Ruslan Horblyuk & April Teitelbaum. (2016) Clinical and economic outcomes by first-line treatment among women with HR+/HER2– metastatic breast cancer in a large US health plan database. Current Medical Research and Opinion 32:8, pages 1417-1423.
Read now
Read now
Nanxin Li, Yanni Hao, Andrew Kageleiry, Miranda Peeples, Anna Fang, Valerie Koo, Eric Q. Wu & Annie Guérin. (2016) Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. Current Medical Research and Opinion 32:2, pages 385-394.
Read now
Read now
Articles from other publishers (37)
Luis Fein, Nicolas Lazaretti, Yamil López Chuken, J. Rogelio González Ramírez Benfield, Max S. Mano, Jose Lobaton, Ernesto Korbenfeld, Fernanda Damian, Dongrui R. Lu, Ave Mori, Shem J. Patyna & Sandra Franco. (2023) Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate. Clinical Drug Investigation.
Crossref
Crossref
Tobias Engler, Peter A. Fasching, Diana Lüftner, Andreas D. Hartkopf, Volkmar Müller, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Markus Wallwiener, Matthias W. Beckmann, Alexander Hein, Erik Belleville, Sabrina Uhrig, Pauline Wimberger, Carsten Hielscher, Christian M. Kurbacher, Rachel Wuerstlein, Michael Untch, Florin-Andrei Taran, Hans-Martin Enzinger, Petra Krabisch, Manfred Welslau, Michael Maasberg, Dirk Hempel, Michael P. Lux, Laura L. Michel, Wolfgang Janni, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm & Andreas Schneeweiss. (2023) Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium – Real-World-Daten aus dem PRAEGNANT-Register. Senologie - Zeitschrift für Mammadiagnostik und -therapie 20:01, pages 43-56.
Crossref
Crossref
Giada Targato, Lucia Bortot, Arianna Dri, Marta Bonotto, Alessandro Marco Minisini, Gianpiero Fasola & Mauro Mansutti. (2022) CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature. Current Oncology 29:12, pages 9630-9639.
Crossref
Crossref
Ignacio Robledo Salas, Florencia Guerra, Lorena Boixadera, María Mateo, Pablo Cresta Morgado, Andrea Aguilar & Valeria Cáceres. (2022) Terapia endocrina para el cáncer de MAMA RH+/HER2- avanzado/metastásico en Argentina. Oncología Clínica 27:1.
Crossref
Crossref
Tobias Engler, Peter A. Fasching, Diana Lüftner, Andreas D. Hartkopf, Volkmar Müller, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Markus Wallwiener, Matthias W. Beckmann, Alexander Hein, Erik Belleville, Sabrina Uhrig, Pauline Wimberger, Carsten Hielscher, Christian M. Kurbacher, Rachel Wuerstlein, Michael Untch, Florin-Andrei Taran, Hans-Martin Enzinger, Petra Krabisch, Manfred Welslau, Michael Maasberg, Dirk Hempel, Michael P. Lux, Laura L. Michel, Wolfgang Janni, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm & Andreas Schneeweiss. (2022) Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT. Geburtshilfe und Frauenheilkunde 82:10, pages 1055-1067.
Crossref
Crossref
F. Miglietta, M. Bottosso, G. Griguolo, M.V. Dieci & V. Guarneri. (2022) Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open 7:2, pages 100409.
Crossref
Crossref
Carlos Barrios, Ruffo Freitas-Junior, Sandro Martins, Jose Bines, Maria Del Pilar Estevez-Diz & Maira Caleffi. (2021) Challenge of Incorporating New Drugs for Breast Cancer in Brazil: A Proposed Framework for Improving Access to Innovative Therapies. JCO Global Oncology:7, pages 474-485.
Crossref
Crossref
Jennifer L. Caswell-Jin, Alison Callahan, Natasha Purington, Summer S. Han, Haruka Itakura, Esther M. John, Douglas W. Blayney, George W. SledgeJrJr, Nigam H. Shah & Allison W. Kurian. (2021) Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. JCO Clinical Cancer Informatics:5, pages 600-614.
Crossref
Crossref
Gustavo Werutsky, Tomás Reinert, Mahira Lopes Rosa & Carlos Henrique Barrios. (2021) Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors. Clinical Breast Cancer 21:6, pages e688-e692.
Crossref
Crossref
Zsuzsanna Kahan, Miguel Gil-Gil, Manuel Ruiz-Borrego, Eva Carrasco, Eva Ciruelos, Montserrat Muñoz, Begoña Bermejo, Mireia Margeli, Antonio Antón, Maribel Casas, Tibor Csöszi, Laura Murillo, Serafín Morales, Lourdes Calvo, Istvan Lang, Emilio Alba, Juan de la Haba-Rodriguez, Manuel Ramos, Isabel Álvarez López, Einav Gal-Yam, Andrés Garcia-Palomo, Elena Alvarez, Santiago González-Santiago, César A. Rodríguez, Sonia Servitja, Massimo Corsaro, Graciela Rodrigálvarez, Christoph Zielinski & Miguel Martín. (2021) Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. European Journal of Cancer 156, pages 70-82.
Crossref
Crossref
Valentina Guarneri, Carlo Alberto Giorgi, Saverio Cinieri, Carmelo Bengala, Gabriella Mariani, Giancarlo Bisagni, Antonio Frassoldati, Claudio Zamagni, Costanza De Rossi, Vito Amoroso, Claudia Andreetta, Antonella Ferro, Alberto Zambelli, Stefania Gori, Ornella Garrone, Maria Vittoria Dieci, Laura Orlando, Ilaria Pastina, Teresa Beninato, Gabriella Moretti, Elisa Genovesi, Margherita Cinefra, Roberto Vicini, Giovanna Magni, Gian L. De Salvo & PierFranco Conte. (2021) Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. European Journal of Cancer 154, pages 21-29.
Crossref
Crossref
Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos Pusztai, Mothaffar F. Rimawi, Rachel Schiff, Grazia Arpino, Sabino De Placido, Aleix Prat & Daniele Generali. (2021) Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers 13:6, pages 1458.
Crossref
Crossref
Yun Wu, Yiqun Han, Pei Yu, Quchang Ouyang, Min Yan, Xiaojia Wang, Xichun Hu, Zefei Jiang, Tao Huang, Zhongsheng Tong, Shusen Wang, Yongmei Yin, Hui Li, Runxiang Yang, Huawei Yang, Yuee Teng, Tao Sun, Li Cai, Hongyuan Li, Xi Chen, Jianjun He, Xinlan Liu, Shune Yang, Youlin Qiao, Jinhu Fan, Jiayu Wang & Binghe Xu. (2021) Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. Frontiers in Oncology 10.
Crossref
Crossref
Eduard Vrdoljak, Joseph Gligorov, Lieve Wierinck, PierFranco Conte, Jacques De Grève, Françoise Meunier, Carlo Palmieri, Luzia Travado, Andrew Walker, Theresa Wiseman, Rachel Wuerstlein, Emilio Alba, Concepción Biurrún, Rosanna D’Antona, Oriol Sola-Morales, Catherine Ubaysi, Roberta Ventura & Fatima Cardoso. (2021) Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe. The Breast 55, pages 79-90.
Crossref
Crossref
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener & Sara Y. Brucker. (2020) Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. The Breast 54, pages 88-95.
Crossref
Crossref
Julien Simon, Marie Chaix, Oumar Billa, Ariane Mamguem Kamga, Patrick Roignot, Sylvain Ladoire, Charles Coutant, Patrick Arveux, Catherine Quantin & Tienhan Sandrine Dabakuyo-Yonli. (2020) Survival in patients with HR+/HER2− metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study. British Journal of Cancer 123:7, pages 1071-1077.
Crossref
Crossref
Antonio Frassoldati, Laura Biganzoli, Roberto Bordonaro, Saverio Cinieri, Pierfranco Conte, Michelino De Laurentis, Lucia Del Mastro, Stefania Gori, Rossella Lauria, Paolo Marchetti, Andrea Michelotti, Filippo Montemurro, Giuseppe Naso, Paolo Pronzato, Fabio Puglisi & Carlo Alberto Tondini. (2020) Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. Future Oncology 16:5, pages 129-145.
Crossref
Crossref
Yeon Hee Park, Tae-Yong Kim, Gun Min Kim, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Kyoung Eun Lee, Hee Kyung Ahn, Moon Hee Lee, Hee-Jun Kim, Han Jo Kim, Jong In Lee, Su-Jin Koh, Ji-Yeon Kim, Kyung-Hun Lee, Joohyuk Sohn, Sung-Bae Kim, Jin-Seok Ahn, Young-Hyuck Im, Kyung Hae Jung, Seock-Ah Im, HK Ahn, EK Cho, IH Park, KS Lee, SS Sim, SJ Hong, MH Chang, JH Kim, YJ Kim, SH Kim, KJ Suh, YH Park, WY Park, YL Choi, JH Yu, YH Im, JS Ahn, JY Hur, SH Park, JY Kim, SJ Nam, JE Lee, SW Kim, SK Lee, SA Im, MS Kim, TY Kim, DY Oh, TY Kim, KH Lee, DW Lee, HJ Kim, KH Jung, SB Kim, JH Ahn, JE Kim, JH Jung, SY Kang, MS Ahn, YW Choi, GM Kim, JH Sohn, MH Kim, SJ Koh, JK Cheon, JI Lee, ST Lim, SY Hyun, KE Lee, HJ Kim, MH Lee, JH Cho & JH Lim. (2019) Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology 20:12, pages 1750-1759.
Crossref
Crossref
Mario Giuliano, Francesco Schettini, Carla Rognoni, Manuela Milani, Guy Jerusalem, Thomas Bachelot, Michelino De Laurentiis, Guglielmo Thomas, Pietro De Placido, Grazia Arpino, Sabino De Placido, Massimo Cristofanilli, Antonio Giordano, Fabio Puglisi, Barbara Pistilli, Aleix Prat, Lucia Del Mastro, Sergio Venturini & Daniele Generali. (2019) Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. The Lancet Oncology 20:10, pages 1360-1369.
Crossref
Crossref
Olivia Le Saux, Audrey Lardy-Cleaud, Sophie Frank, Marc Debled, Paul H. Cottu, Barbara Pistilli, Laurence Vanlemmens, Marianne Leheurteur, Christelle Lévy, Lilian Laborde, Lionel Uwer, Veronique D'hondt, Delphine Berchery, Veronique Lorgis, Jean-Marc Ferrero, Genevieve Perrocheau, Coralie Courtinard, Marie Ange Mouret-Reynier, Michel Velten, Mathias Breton, Damien Parent, Sylvie Chabaud, Mathieu Robain & Thomas Bachelot. (2019) Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. European Journal of Cancer 118, pages 131-141.
Crossref
Crossref
Geneviève Gauthier, Patrick Gagnon-Sanschagrin, Annie Guérin, Rebecca Burne, Tania Small, Polly Niravath & Anand A. Dalal. (2018) Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women. Advances in Therapy 35:4, pages 503-514.
Crossref
Crossref
Deborah Goldschmidt, Anand A. Dalal, Hela Romdhani, Sneha Kelkar, Annie Guerin, Genevieve Gauthier, Eric Q. Wu, Polly Niravath & Tania Small. (2018) Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study. Advances in Therapy 35:4, pages 482-493.
Crossref
Crossref
Gül A. Başaran, Chris Twelves, Véronique Diéras, Javier Cortés & Ahmad Awada. (2018) Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treatment Reviews 63, pages 144-155.
Crossref
Crossref
Andreas D. Hartkopf, Jens Huober, Bernhard Volz, Naiba Nabieva, Florin-Andrei Taran, Judith Schwitulla, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Michael P. Lux, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Matthias Geberth, Nikos Fersis, Wolfgang Abenhardt, Christian Kurbacher, Rachel Wuerstlein, Christoph Thomssen, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Diethelm Wallwiener, Sara Y. Brucker & Andreas Schneeweiss. (2018) Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry. The Breast 37, pages 42-51.
Crossref
Crossref
Volkmar Müller, Naiba Nabieva, Lothar Häberle, Florin-Andrei Taran, Andreas D. Hartkopf, Bernhard Volz, Friedrich Overkamp, Anna Lisa Brandl, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Johannes Ettl, Michael P. Lux, Diana Lüftner, Erik Belleville, Peter A. Fasching, Wolfgang Janni, Matthias W. Beckmann, Pauline Wimberger, Carsten Hielscher, Tanja N. Fehm, Sara Y. Brucker, Diethelm Wallwiener, Andreas Schneeweiss & Markus Wallwiener. (2018) Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. The Breast 37, pages 154-160.
Crossref
Crossref
Junichiro Watanabe, T. Hayashi, Y. Tadokoro, S. Nishimura & K. Takahashi. (2017) Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution. Breast Cancer Research and Treatment 166:3, pages 911-917.
Crossref
Crossref
Yeon Hee Park, Seock-Ah Im, Sung-Bae Kim, Joo Hyuk Sohn, Keun Seok Lee, Yee Soo Chae, Ki Hyeong Lee, Jee Hyun Kim, Young-Hyuck Im, Ji-Yeon Kim, Tae-Yong Kim, Kyung-Hun Lee, Jin-Hee Ahn, Gun Min Kim, In Hae Park, Soo Jung Lee, Hye Sook Han, Se Hyun Kim & Kyung Hae Jung. (2017) Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. European Journal of Cancer 86, pages 385-393.
Crossref
Crossref
Paolo Marchetti, Nicolai Maass, Joseph Gligorov, Karin Berger, Finlay MacDougall, Jukka Montonen & Jan Lewis. (2017) Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective. The Breast 32, pages 247-255.
Crossref
Crossref
Marta Bonotto, Lorenzo Gerratana, Massimo Di Maio, Carmine De Angelis, Marika Cinausero, Stefano Moroso, Monica Milano, Brigida Stanzione, Piera Gargiulo, Donatella Iacono, Alessandro Marco Minisini, Mauro Mansutti, Gianpiero Fasola, Sabino De Placido, Grazia Arpino & Fabio Puglisi. (2017) Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. The Breast 31, pages 114-120.
Crossref
Crossref
Elżbieta Senkus & Aleksandra Łacko. (2017) Over-treatment in metastatic breast cancer. The Breast 31, pages 309-317.
Crossref
Crossref
Rita Caldeira & Mark Scazafave. (2016) Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States. Oncology and Therapy 4:2, pages 189-197.
Crossref
Crossref
Luisa Carbognin, Isabella Sperduti, Mariangela Ciccarese, Alessandra Fabi, Luciana Petrucelli, Sabrina Vari, Rosa Chiara Forcignanò, Rolando Nortilli, Cecilia Vicentini, Sara Pilotto, Sara Merler, Ilaria Zampiva, Matteo Brunelli, Erminia Manfrin, Diana Giannarelli, Giampaolo Tortora & Emilio Bria. (2016) Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival. The Breast 29, pages 24-30.
Crossref
Crossref
D.J.A. Lobbezoo, R.J.W. van Kampen, A.C. Voogd, M.W. Dercksen, F. van den Berkmortel, T.J. Smilde, A.J. van de Wouw, F.P.J. Peters, J.M.G.H. van Riel, N.A.J.B. Peters, M. de Boer, P.G.M. Peer & V.C.G. Tjan-Heijnen. (2016) In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Annals of Oncology 27:2, pages 256-262.
Crossref
Crossref
Uwe Güth, Dorothy Jane Huang, Andreas Schötzau & Seraina Margaretha Schmid. (2016) Use of Palliative Endocrine Therapy in Patients with Hormone Receptor-Positive Distant Metastatic Breast Cancer: How Often, How Effective, How Long?. Oncology 90:1, pages 1-9.
Crossref
Crossref
Mutsuko Yamamoto-Ibusuki, Monica Arnedos & Fabrice André. (2015) Targeted therapies for ER+/HER2- metastatic breast cancer. BMC Medicine 13:1.
Crossref
Crossref
Daniele Generali, Sergio Venturini, Carla Rognoni, Oriana Ciani, Lajos Pusztai, Sherene Loi, Guy Jerusalem, Alberto Bottini & Rosanna Tarricone. (2015) A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment 152:1, pages 95-117.
Crossref
Crossref
Adam M. Brufsky. (2015) Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer. Clinical Medicine Insights: Oncology 9, pages CMO.S31586.
Crossref
Crossref